论文部分内容阅读
目的:探讨吉非替尼联合紫杉醇诱导人卵巢癌细胞凋亡的影响。方法:吉非替尼单独或联合紫杉醇作用卵巢癌HO8910细胞,以蛋白质印迹法检测EGFR下游信号磷酸化Akt(p-Akt)、磷酸化细胞外信号调节激酶(p-ERK)和细胞核增殖抗原(PCNA),以MTT法检测细胞增殖率,FCM法检测细胞周期分布和凋亡。结果:吉非替尼单用在0.25～4.00μmol/L浓度范围内呈浓度依赖性抑制卵巢癌HO8910细胞增殖,1.0μmol/L浓度单独作用24h则细胞周期主要分布于G1期,p-Akt、p-ERK和PCNA蛋白水平下降,72h时细胞凋亡增加,与对照组比较,差异均有统计学意义,P<0.05。吉非替尼与紫杉醇合用不仅能更显著的抑制细胞增殖,而且凋亡细胞显著增加(P<0.05),与对应浓度单用紫杉醇比较,差异均有统计学意义,P<0.05。结论:吉非替尼与紫杉醇合用能显著抑制卵巢癌HO8910细胞增殖、诱导凋亡,两种药物合用具有协同作用。
Objective: To investigate the effect of gefitinib and paclitaxel on the apoptosis of human ovarian cancer cells. METHODS: Gefitinib, alone or in combination with paclitaxel, was used to detect the expression of phosphorylated Akt (p-Akt), phosphorylated extracellular signal-regulated kinase (p-ERK) and nuclear proliferative antigens PCNA). Cell proliferation rate was detected by MTT assay. Cell cycle distribution and apoptosis were detected by FCM. RESULTS: Gefitinib alone inhibited proliferation of HO8910 ovarian cancer cells in a concentration-dependent manner at a concentration range of 0.25-4.00 μmol / L. After treated with 1.0 μmol / L for 24 hours, the cell cycle distribution was mainly in G1 phase. The expression of p-Akt, The protein levels of p-ERK and PCNA decreased, and the apoptosis increased at 72h. There were significant differences between the two groups (P <0.05). The combination of gefitinib and paclitaxel not only significantly inhibited cell proliferation but also significantly increased the apoptotic cells (P <0.05). Compared with paclitaxel alone, the difference was statistically significant (P <0.05). Conclusion: Combination of gefitinib and paclitaxel can significantly inhibit the proliferation and induce apoptosis of HO8910 ovarian cancer cells, and the combination of the two drugs has a synergistic effect.